Strategic Alliance
Partnership between
small to mid-size
(Bio)Pharma companies
and CRO industry
Axel Mescheder, M.D.
VP Medical & Regulatory Affairs
Europe
FOCUSED. TRUSTED. GLOBAL.
Key Topics
o What is a partnership?
o The current business landscape
o Key factors for success in strategic partnerships
o Typical obstacles and how to overcome them
o Measures for success
o Case study presentation
FOCUSED. TRUSTED. GLOBAL.
What is a Partnership?
o A shared goal
o An agreement on the methods or
standards
o A plan to measure success and
correct actions
o A forum
FOCUSED. TRUSTED. GLOBAL.
Why Develop a Partnership?
o Increase the visibility of the Sponsor and
program within the CRO
o Streamline communication and escalation pathways
o Benefit from senior level medical, scientific and
operational oversight
FOCUSED. TRUSTED. GLOBAL.
Mid-size vs Large Pharma
o Mid-size - Greater openness to true partnering
Volume + partnering = True savings
Willingness to follow CROs SOPs and best practices
Achieve short and long term benefits
o Large Pharma rarely partner:
Contract for volume
Require CRO to model their processes
Generate short term savings
Results in costly changes to procurement practices
FOCUSED. TRUSTED. GLOBAL.
Current Business Landscape
FOCUSED. TRUSTED. GLOBAL.
The Situation
o Pharmaceutical and biotech industry under
increasing pressure
Patent expiry, generic competition, declining
revenues
Strong demand for increased efficiency
Concerns about pipeline/lack of blockbuster targets
Increased regulatory oversight
International competition
Increased frequency and value of strategic
partnerships
FOCUSED. TRUSTED. GLOBAL.
Biotech Challenges
o Strategic considerations in drug development
and outsourcing considerations
Program planning
Regulatory strategy (global)
End game for company
Competition
FOCUSED. TRUSTED. GLOBAL.
Market Trends
Z. Brennan, Outsourcing Pharma, 07Apr2014; Frost & Sullivan, PR newswire, 27Mar2014
o Smaller biotech, pharma and medical device companies expand R&D business
o Trend to cooperate with mid-size CROs
o Increased emphasize on expertise and quality management
o EU CRO market expected to reach $13.52 billion (2015) up from $7.10 billion (2008) with biomarkers as future growth driver
o Opportunity for full service CROs with scale, global capabilities and expertise
FOCUSED. TRUSTED. GLOBAL.
Hurdles to Overcome
o Getting companies to understand
outsourcing models
o Smaller companies assume they
cannot enter into strategic
outsourcing
o Internal disputes over what to
outsource
o Complexity of CRO selection is
increasing
o RFPs are becoming longer and
more complex
o 2/3 of companies do not use
preferred vendors or negotiate
master service agreements
(MSAs) with CROs
FOCUSED. TRUSTED. GLOBAL.
Overall Market Size and Growth
FOCUSED. TRUSTED. GLOBAL.
Outsourced Phase I-IV Development Spending
FOCUSED. TRUSTED. GLOBAL.
Service-line Distribution
2014 Service-line distribution (%) of the CRO market size 2014
Clinical Monitoring 22.1%
Investigator Payments 13.5%
Data Management 11.4%
Laboratory 10.9%
Project Management 10.0%
Patient and site Recruitment 8.5%
Biostatistics 6.6%
Technology 6.6%
Medical Writing 3.5%
Regulatory 3.0%
Quality Assurance 2.6%
Other 1.3%
Total 100%
FOCUSED. TRUSTED. GLOBAL.
Development Ph I-IV Distribution
2014 Development phase (%) of the CRO market size 2014
Phase I 23.0%
Phase II 26.9%
Phase III 38.8%
Phase IV 11.6%
Total 100%
2014 Development phase ($B) of the CRO market size 2014
Phase I $5.4
Phase II $6.3
Phase III $9.1
Phase IV $2.7
Total $23.6B
FOCUSED. TRUSTED. GLOBAL.
Top 10 Attributes Sponsors use when Choosing a
Service Provider
o Low cost
o Therapeutic expertise
o Patient recruitment strategy
o Prior positive experience with service provider
o Project manager quality
o Network of sites / investigators
o Responsiveness
o Metrics for meeting overall project timelines
o CRA quality
o Up-front contingency planning, risk management
www.ISRreports.com 2014 | CRO Quality Benchmarking Phase II/III Service Providers (2014)
FOCUSED. TRUSTED. GLOBAL.
Structuring a Partnership
o Multi-tiered governance and oversight Executive Committee
Operations Committee
Program Management Team
o Operating charter - governance details of the partnership Partnership principles
Escalation pathway
Objectives of each committee
KPIs and metrics to be measured and evaluated
Meeting documentation and follow-up, includes lessons-learned and process improvements
FOCUSED. TRUSTED. GLOBAL.
Measure Success
o Quality Process Audits
Regulatory Authority Audits
Protocol Deviations
o Clinical Milestones Actual versus contracted
Final protocol to all sites activated
Final protocol to last patient last visit (LPLV)
LPLV to database lock (DL)
DL to final study report
o Contract and Cost Management Actual versus contracted
Change in scope management
FOCUSED. TRUSTED. GLOBAL.
Case Study: The Situation
o Small biotech (limited internal resources)
o Autologous immunotherapy (increased
complexity)
o 12 months = 29 newly qualified / 0 active sites
o No dedicated CRO team
o The integrated system CTMS, DM, IVRS had to be built
o First global Ph3 oncology trial for incumbent
CRO
FOCUSED. TRUSTED. GLOBAL.
The Solution
o Experienced in global oncology Phase III studies
o Centralized model for startup, project management, data management
o Proven, highly customizable technology -CTMS/IVRS/EDC
o Dedicated CTMs, CRAs, regulatory, and start-up team including project management, regulatory, and legal
o Single-minded dedication to activate 50 sites to ensure accrual began within four months of transition
o Flexible approach
FOCUSED. TRUSTED. GLOBAL.
Communication and Take Away
o True partnership extension of Sponsor company
o Process not impeding progress
o Mutual respect
o Common goal
o Timing not waiting until its too late
o Dont be afraid to fail
o Have a map not a plan
o Communication and flexibility
FOCUSED. TRUSTED. GLOBAL.
Conclusion
o Developing a partnership requires time,
commitment and expertise
o The long-term benefits of a partnership exceed the investment needed to create and sustain it
o A well thought out strategic partnership
between a Sponsor and a CRO results in the optimization of quality, time, and money
Top Related